vs
Side-by-side financial comparison of NEXPOINT DIVERSIFIED REAL ESTATE TRUST (NXDT) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.
NEXPOINT DIVERSIFIED REAL ESTATE TRUST is the larger business by last-quarter revenue ($18.4M vs $13.2M, roughly 1.4× TriSalus Life Sciences, Inc.). TriSalus Life Sciences, Inc. runs the higher net margin — -73.9% vs -193.1%, a 119.2% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs -29.0%). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs 19.9%).
NexPoint Diversified Real Estate Trust is a publicly traded US real estate investment trust. It acquires, manages and optimizes a diversified portfolio covering multifamily housing, industrial facilities, offices and neighborhood retail, generating returns via rental income and long-term property value appreciation.
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
NXDT vs TLSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.4M | $13.2M |
| Net Profit | $-35.5M | $-9.8M |
| Gross Margin | — | 86.7% |
| Operating Margin | -18.8% | -24.8% |
| Net Margin | -193.1% | -73.9% |
| Revenue YoY | -29.0% | 59.8% |
| Net Profit YoY | -291.1% | 3.5% |
| EPS (diluted) | $-0.73 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.4M | $13.2M | ||
| Q3 25 | $17.5M | $11.6M | ||
| Q2 25 | $21.0M | $11.2M | ||
| Q1 25 | $29.1M | $9.2M | ||
| Q4 24 | $25.9M | $8.3M | ||
| Q3 24 | $22.2M | $7.3M | ||
| Q2 24 | $22.3M | $7.4M | ||
| Q1 24 | $12.8M | $6.5M |
| Q4 25 | $-35.5M | $-9.8M | ||
| Q3 25 | $-13.7M | $-10.8M | ||
| Q2 25 | $-45.3M | $-8.3M | ||
| Q1 25 | $-34.3M | $-10.4M | ||
| Q4 24 | $-9.1M | $-10.1M | ||
| Q3 24 | $-10.0M | $-2.4M | ||
| Q2 24 | $-9.8M | $-4.3M | ||
| Q1 24 | $-22.7M | $-13.2M |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 83.5% | ||
| Q2 25 | — | 83.9% | ||
| Q1 25 | — | 83.7% | ||
| Q4 24 | — | 85.3% | ||
| Q3 24 | — | 86.3% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.0% |
| Q4 25 | -18.8% | -24.8% | ||
| Q3 25 | -19.1% | -77.9% | ||
| Q2 25 | -0.6% | -65.4% | ||
| Q1 25 | 19.0% | -79.9% | ||
| Q4 24 | 3.6% | -91.8% | ||
| Q3 24 | -26.8% | -118.9% | ||
| Q2 24 | 2.7% | -111.0% | ||
| Q1 24 | 2.1% | -180.8% |
| Q4 25 | -193.1% | -73.9% | ||
| Q3 25 | -78.4% | -93.5% | ||
| Q2 25 | -215.1% | -73.9% | ||
| Q1 25 | -118.0% | -113.2% | ||
| Q4 24 | -35.0% | -122.4% | ||
| Q3 24 | -45.2% | -32.6% | ||
| Q2 24 | -43.9% | -58.8% | ||
| Q1 24 | -177.3% | -204.5% |
| Q4 25 | $-0.73 | $-0.22 | ||
| Q3 25 | $-0.29 | $-0.96 | ||
| Q2 25 | $-0.99 | $-0.27 | ||
| Q1 25 | $-0.80 | $-0.39 | ||
| Q4 24 | $-0.20 | $-0.38 | ||
| Q3 24 | $-0.25 | $-0.12 | ||
| Q2 24 | $-0.24 | $-0.21 | ||
| Q1 24 | $-0.59 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.2M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $700.1M | $-33.9M |
| Total Assets | $1.1B | $35.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.2M | $20.4M | ||
| Q3 25 | $5.3M | $22.7M | ||
| Q2 25 | $4.7M | $26.5M | ||
| Q1 25 | $9.5M | $13.0M | ||
| Q4 24 | $8.8M | $8.5M | ||
| Q3 24 | $8.5M | $11.3M | ||
| Q2 24 | $28.4M | $16.5M | ||
| Q1 24 | $20.2M | $4.0M |
| Q4 25 | $700.1M | $-33.9M | ||
| Q3 25 | $739.0M | $-26.7M | ||
| Q2 25 | $752.7M | $-19.4M | ||
| Q1 25 | $802.7M | $-34.4M | ||
| Q4 24 | $836.5M | $-25.9M | ||
| Q3 24 | $842.9M | $-20.4M | ||
| Q2 24 | $859.1M | $-25.3M | ||
| Q1 24 | $863.0M | $-36.0M |
| Q4 25 | $1.1B | $35.3M | ||
| Q3 25 | $1.1B | $36.5M | ||
| Q2 25 | $1.1B | $41.3M | ||
| Q1 25 | $1.2B | $28.6M | ||
| Q4 24 | $1.2B | $24.0M | ||
| Q3 24 | $1.2B | $27.5M | ||
| Q2 24 | $1.2B | $32.4M | ||
| Q1 24 | $1.1B | $17.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-2.5M |
| Free Cash FlowOCF − Capex | — | $-2.5M |
| FCF MarginFCF / Revenue | — | -19.1% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $-2.5M | ||
| Q3 25 | $835.0K | $-3.7M | ||
| Q2 25 | $75.0K | $-7.3M | ||
| Q1 25 | $7.1M | $-4.5M | ||
| Q4 24 | $-11.7M | $-5.7M | ||
| Q3 24 | $497.0K | $-10.8M | ||
| Q2 24 | $-5.5M | $-13.4M | ||
| Q1 24 | $-2.6M | $-10.9M |
| Q4 25 | — | $-2.5M | ||
| Q3 25 | — | $-3.9M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-5.3M | ||
| Q4 24 | — | $-5.8M | ||
| Q3 24 | — | $-11.0M | ||
| Q2 24 | — | $-13.5M | ||
| Q1 24 | — | $-10.9M |
| Q4 25 | — | -19.1% | ||
| Q3 25 | — | -33.9% | ||
| Q2 25 | — | -66.1% | ||
| Q1 25 | — | -57.3% | ||
| Q4 24 | — | -69.7% | ||
| Q3 24 | — | -149.9% | ||
| Q2 24 | — | -183.1% | ||
| Q1 24 | — | -169.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 1.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
